LMRI:NASDAQLumexa Imaging Holdings, Inc. Analysis

Lumexa Imaging is trading near its 20‑day SMA at roughly $10, but sits well below the 50‑day (≈$12.3) and 200‑day (≈$14.0) averages, indicating a short‑term bearish bias. The RSI of 44 suggests neutral momentum while the MACD histogram is modestly positive, hinting at a potential technical bounce. However, volume is on a decreasing trend and the 30‑day volatility exceeds 120%, compounded by a beta of nearly 2.8, underscoring heightened price swings. On the fundamentals side, revenue grew 7.9% YoY to just over $1 bn and adjusted EBITDA surged 18.6%, yet the company still posts a negative profit margin and a ROE of –12.6%, reflecting ongoing profitability challenges. The balance sheet is leveraged, with debt over $960 m dwarfing cash of $58 m, resulting in a debt‑to‑equity ratio above 160%. Despite these headwinds, the forward PE of ~10 is well beneath the industry average of 26, and analysts collectively rate the stock as a strong buy with a median price target near $22, implying upside potential of over 100%.